You are here: Industry Insights > RMS

News List

MHRA nod for Janssen’s relapsing multiple sclerosis drug Ponvory pharmatimes
August 12, 2021
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Ponvory (ponesimod) for the treatment relapsing multiple sclerosis (RMS).
European Commission approves PONVORY™ --- A Once Daily Oral Treatment for Adults with Relapsing Forms of Multiple Sclerosis americanpharmaceuticalreview
May 25, 2021
Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced that the European Commission (EC) has approved PONVORY™ (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by ...
Charles River Laboratories generates $824 million in first quarter europeanpharmaceuticalreview
May 07, 2021
Charles River Laboratories International’s first quarter revenue was approximately 17 percent higher in Q1 2021, with organic revenue growth of 13 percent.
EC approves Novartis’s Kesimpta for relapsing multiple sclerosis pharmaceutical-technology
April 01, 2021
The European Commission has approved Novartis’s Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features.
FDA approves Zeposia® (ozanimod) to treat relapsing forms of multiple sclerosis europeanpharmaceuticalreview
March 31, 2020
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.
BMS' ZEPOSIA Wins Approval for RMS contractpharma
March 30, 2020
Oral medication offers RMS patients an initiation with no genetic test and no label-based first-dose observation required.
FDA and EMA accept licence applications for multiple sclerosis treatment europeanpharmaceuticalreview
March 04, 2020
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).